$RNTX Cashflow Statement | Understand Stock

$RNTX

$0.70 +$0.12 (20.75%) Close

$RNTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Commitment fee related to Pre-Paid Advance agreement
Original issue discount related to Pre-Paid Advance agreement
Depreciation and amortization expense
Net amortization of premiums and discounts on investments
Stock-based compensation expense
Forgiveness of Paycheck Protection Program loan
Gain on sale of property and equipment
Impairment loss on intangible assets
Loss on disposition of property and equipment
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other assets
Accounts payable
Operating lease liabilities
Accrued expenses and other current liabilities
Other long-term liabilities
Deferred tax liabilities

Net cash used in operating activities
Cash flows from investing activities:
Proceeds from sale of property and equipment
Purchases of investments
Proceeds from sales or maturities of investments
Acquisition, net of cash acquired
Purchases of property and equipment
Net cash provided by investing activities

Cash flows from financing activities:
Proceeds from issuance of common stock, common warrants and pre-funded warrants, net of issuance costs
Proceeds from Financing
Proceeds from issuance of common stock, net of offering costs
Lung Acquisition
Total proceeds from issuance of common stock, net of offering costs
Proceeds from Pre-Paid Advances, net of discounts
Proceeds from the PIPE Financing
Proceeds from issuance of common stock in connection with stock option exercises
Proceeds from issuance of common stock in connection with Warrant Exercises, net of costs
Proceeds from issuance of warrants, net of offering costs
Proceeds from Warrant Exchanges, net of offering costs
Proceeds from warrant exercises with common stock subscribed
Net cash provided by financing activities

Effect of exchange rate changes on cash and cash equivalents
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Lung Acquisition
Total cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Lung Acquisition
Total cash and cash equivalents at end of year
Supplemental disclosure of non-cash investing and financing activities:
Unrealized gain on short-term investments
Unrealized (loss) gain on short-term investments
Foreign currency translation adjustments
Issuance of common stock for Pre-Paid Advances and interest accrual
Conversion of Series X non-voting convertible preferred stock into common stock shares
Restricted cash at end of year

Comments